BT-474 Cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Breast cancer cell lines

Organism

Human

Donor History

Invasive ductal carcinoma

Growth Properties

The cells grow in compact

,

slowly growing multi-layered colonies which rarely become confluent. A confluent monolayer is not formed.

Growth Conditions

Culture medium: DMEM:Ham's F12 (1:1)

,

w: 3.1 g/L Glucose

,

w: 2.5 mM L-Glutamine

,

w: 15 mM HEPES

,

w: 0.5 mM Sodium pyruvate

,

w: 1.2 g/L NaHCO3 (Cytion article number 820400a). Supplements: Supplement the medium with 10% FBS

,

10 microgram/mL Insulin. Seeding density: 2 x 10⁴ cells/cm² will yield in a mostly confluent layer in about 4 days. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/BT-474-Cells/300131

SKU: 300131 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

BT-474 is a human breast cancer cell line, derived from the ductal carcinoma of a 60-year-old female. This cell line is estrogen and progesterone receptor positive, making it a valuable model for studying hormone-responsive breast cancers. BT-474 cells are also characterized by the overexpression of HER2/neu (human epidermal growth factor receptor 2), a protein that is amplified and plays a critical role in the pathogenesis and progression of certain aggressive types of breast cancer.

The BT-474 cell line is extensively used in oncological research to study the molecular mechanisms of breast cancer proliferation and to test therapeutic strategies targeting hormone receptors and the HER2 pathway. These cells are particularly useful for examining the efficacy of HER2-targeted therapies, such as trastuzumab (Herceptin), and for exploring mechanisms of resistance to these treatments. The cell line has also contributed to advancements in understanding how hormonal manipulations affect cancer cell growth and survival, providing insights into potential treatment approaches for hormone-dependent tumors.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.